ORCHESTRA BIOMED HOLDINGS IN (OBIO)
US68572M1062 - Common Stock
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Let's take a look at the stocks that are in motion in today's session.
Orchestra BioMed Holdings Becomes Oversold (OBIO)
OBIO Crosses Above Key Moving Average Level
OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024
OBIO stock results show that Orchestra BioMed Hldgs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orchestra BioMed Hldgs (NASDAQ:OBIO) just reported results for the second quart...
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical...
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
Jayme Strauss and Mike Kaswan join as Chief Clinical and Commercial Officer and Chief Financial Officer, respectively, as the company progresses toward FDA clearance
OBIO Crosses Below Key Moving Average Level
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical...
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company...
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024
OBIO stock results show that Orchestra BioMed Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orchestra BioMed Hldgs (NASDAQ:OBIO) just reported results for the first quarte...
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
Company hosting in-person R&D day event, focused on atrioventricular interval modulation (“AVIM”) therapy, including the unmet need in hypertension,...
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
Patent estate covering atrioventricular interval modulation (“AVIM”) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that...
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
Orchestra BioMed Holdings is Now Oversold (OBIO)
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023
OBIO stock results show that Orchestra BioMed Hldgs beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orchestra BioMed Hldgs (NASDAQ:OBIO) just reported results for the fourth quart...
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive...
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice...
Orchestra BioMed Holdings Enters Oversold Territory (OBIO)
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
Orchestra BioMed to Participate in Upcoming Investor Conferences
Orchestra BioMed to Participate in Upcoming Investor Conferences
NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical...
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive...
Orchestra BioMed Holdings Breaks Above 200-Day Moving Average - Bullish for OBIO
Jefferies starts Orchestra BioMed at buy, cites lead program opportunities
Jefferies has initiated coverage of Orchestra BioMed (OBIO) with a buy rating, citing the market opportunities for its two lead programs. Read more here.
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive...
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in...